Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera



   Halozyme Announced Roche Filed A Marketing Authorization Application For
                            Subcutaneous MabThera

Filing Triggered a $4 Million Milestone Payment to Halozyme From Roche

Data From Subcutaneous MabThera Trials Presented at the American Society of
Hematology Annual Meeting

PR Newswire

SAN DIEGO, Dec. 8, 2012

SAN DIEGO, Dec. 8, 2012 /PRNewswire/ --  Halozyme Therapeutics, Inc. (NASDAQ:
HALO) today announced that Roche has submitted a line extension application to
the European Medicines Agency for a subcutaneous (SC) formulation of
MabThera^® (rituxumab). The filing of the application triggered a $4 million
milestone payment to Halozyme under the License and Collaboration Agreement
between Halozyme and Roche.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"This regulatory filing brings patients and physicians one step closer to an
enhanced treatment option for Non-Hodgkin Lymphoma," said Gregory I. Frost,
Ph.D., Halozyme's President and Chief Executive Officer. "Offering a
subcutaneous formulation of MabThera could provide patients with a therapy
which is less invasive, shortens administration times and potentially reduces
healthcare costs."

Roche reported positive data today from two clinical studies of MabThera given
by subcutaneous injection at the 54^th annual meeting of the American Society
of Hematology (ASH). The pivotal study data presented showed that SC
administration of MabThera enabled the delivery of MabThera over approximately
five minutes without compromising its proven efficacy and safety. Both studies
showed that a fixed dose of MabThera can be administered subcutaneously,
potentially allowing patients to spend less time in infusion centers receiving
their MabThera treatment. Specifically, the studies showed that SC injection
resulted in non-inferior MabThera concentrations in the blood
(pharmacokinetics; PK) compared with standard intravenous (IV) infusion.
Overall, SC and IV adverse event profiles were similar and administration
related reactions were mostly of mild to moderate intensity. (For more
detailed information on the studies, see Roche's media release issued earlier
today.)

Currently, MabThera is available as an IV formulation. MabThera SC uses
Halozyme's Enhanze™ Technology which enables the injection of large volumes of
a medication under the skin. In a clinical study, patients were able to
receive MabThera over approximately 5 minutes via SC injection versus a few
hours with IV-infused MabThera.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing
and commercializing innovative products that advance patient care. With a
diversified portfolio of enzymes that target the extracellular matrix, the
Company's research focuses primarily on a family of human enzymes, known as
hyaluronidases, that increase the absorption and dispersion of biologics.
Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology
and dermatology that have significant unmet medical need. The Company markets
HYLENEX^® recombinant (hyaluronidase human injection) and has partnerships
with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San
Diego, CA. For more information on how we are innovating, please visit our
corporate website at www.halozyme.com.

Safe Harbor Statement

In addition to historical information, the statements set forth above include
forward-looking statements (including, without limitation, statements
concerning the potential regulatory approval and commercial availability of
MabThera SC and the potential benefits and attributes of MabThera SC) that
involve risk and uncertainties that could cause actual results to differ
materially from those in the forward-looking statements. The forward-looking
statements are also identified through use of the words "believe," "enable,"
"may," "will," "could," "intends," "estimate," "anticipate," "plan,"
"predict," "probable," "potential," "possible," "should," "continue," and
other words of similar meaning. Actual results could differ materially from
the expectations contained in forward-looking statements as a result of
several factors, including unexpected clinical trial results, delays in
development and regulatory review, regulatory approval requirements,
unexpected adverse event and competitive conditions. These and other factors
that may result in differences are discussed in greater detail in the
company's reports on Forms 10-K, 10-Q, and other filings with the Securities
and Exchange Commission.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
+1-858-704-826
aerickson@halozyme.com

SOURCE Halozyme Therapeutics, Inc.

Website: http://www.halozyme.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement